Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer's disease

被引:44
|
作者
Venkataraman, Ashwin V. [1 ,2 ]
Mansur, Ayla [3 ]
Rizzo, Gaia [1 ,3 ]
Bishop, Courtney [3 ]
Lewis, Yvonne [3 ]
Kocagoncu, Ece [4 ]
Lingford-Hughes, Anne [1 ]
Huiban, Mickael [3 ]
Passchier, Jan [3 ]
Rowe, James B. [4 ]
Tsukada, Hideo [5 ]
Brooks, David J. [6 ,7 ]
Martarello, Laurent [8 ]
Comley, Robert A. [9 ]
Chen, Laigao [10 ]
Schwarz, Adam J. [11 ]
Hargreaves, Richard [12 ]
Gunn, Roger N. [1 ,3 ]
Rabiner, Eugenii A. [3 ,13 ]
Matthews, Paul M. [1 ,2 ]
机构
[1] Imperial Coll London, Dept Brain Sci, London W12 0NN, England
[2] Imperial Coll London, UK Dementia Res Inst, London W12 0NN, England
[3] Invicro LLC, London W12 0NN, England
[4] Univ Cambridge, Cambridge CB2 2QQ, England
[5] Hamamatsu Photon KK, Hamamatsu, Shizuoka 4348601, Japan
[6] Newcastle Univ, Newcastle NE2 4HH, England
[7] Aarhus Univ, Dept Clin Med, DK-8200 Aarhus, Denmark
[8] Biogen, Cambridge, MA 02142 USA
[9] AbbVie, N Chicago, IL USA
[10] Pfizer Inc, Cambridge, MA 02139 USA
[11] Takeda Pharmaceut Ltd, Cambridge, MA 02139 USA
[12] Bristol Myers Squibb, Princeton, NJ 08543 USA
[13] Kings Coll London, London SE5 8AF, England
基金
英国医学研究理事会;
关键词
IN-VIVO EVALUATION; POSITRON-EMISSION-TOMOGRAPHY; OXIDATIVE STRESS; AMYLOID DEPOSITION; RECEPTOR-BINDING; BRAIN; SIGMA(1); ATROPHY; SA4503; LIGAND;
D O I
10.1126/scitranslmed.abk1051
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cell stress and impaired oxidative phosphorylation are central to mechanisms of synaptic loss and neurodegeneration in the cellular pathology of Alzheimer's disease (AD). In this study, we quantified the in vivo expression of the endoplasmic reticulum stress marker, sigma 1 receptor (S1R), using [C-11]SA4503 positron emission tomography (PET), the mitochondrial complex I (MC1) with [F-18]BCPP-EF, and the presynaptic vesicular protein SV2A with [C-11]UCB-J in 12 patients with early AD and in 16 cognitively normal controls. We integrated these molecular measures with assessments of regional brain volumes and cerebral blood flow ( CBF) measured with magnetic resonance imaging arterial spin labeling. Eight patients with AD were followed longitudinally to estimate the rate of change of the physiological and structural pathology markers with disease progression. The patients showed widespread increases in S1R (<= 27%) and regional reduction in MC1 (>= -28%) and SV2A (>= -25%) radioligand binding, brain volume (>= -23%), and CBF (>= -26%). [F-18]BCPP-EF PET MC1 binding (>= -12%) and brain volumes (>= -5%) showed progressive reductions over 12 to 18 months, suggesting that they both could be used as pharmacodynamic indicators in early-stage therapeutics trials. Associations of reduced MC1 and SV2A and increased S1R radioligand binding with reduced cognitive performance in AD, although exploratory, suggested a loss of metabolic functional reserve with disease. Our study thus provides in vivo evidence for widespread, clinically relevant cellular stress and bioenergetic abnormalities in early AD.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer's disease
    Pohland, Maximilian
    Pellowska, Maren
    Asseburg, Heike
    Hagl, Stephanie
    Reutzel, Martina
    Joppe, Aljoscha
    Berressem, Dirk
    Eckert, Schamim H.
    Wurglics, Mario
    Schubert-Zsilavecz, Manfred
    Eckert, Gunter P.
    ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [32] Early diagnosis of Alzheimer's disease
    Saint-Aubert, L.
    Puel, M.
    Chollet, F.
    Pariente, J.
    REVUE NEUROLOGIQUE, 2012, 168 (11) : 825 - 832
  • [33] Mitochondrial dysfunction and cellular metabolic deficiency in Alzheimer's disease
    Gu, Xue-Mei
    Huang, Han-Chang
    Jiang, Zhao-Feng
    NEUROSCIENCE BULLETIN, 2012, 28 (05) : 631 - 640
  • [34] Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease
    Guo, Lan
    Tian, Jing
    Du, Heng
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 57 (04) : 1071 - 1086
  • [35] Mitochondrial Dysfunction: Different Routes to Alzheimer's Disease Therapy
    Picone, Pasquale
    Nuzzo, Domenico
    Caruana, Luca
    Scafidi, Valeria
    Di Carlo, Marta
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2014, 2014
  • [36] Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium
    Singulani, Monique P.
    De Paula, Vanessa J. R.
    Forlenza, Orestes, V
    NEUROSCIENCE LETTERS, 2021, 760
  • [37] Mitochondrial Dysfunction in Alzheimer's Disease: Opportunities for Drug Development
    Bhatia, Shiveena
    Rawal, Rishi
    Sharma, Pratibha
    Singh, Tanveer
    Singh, Manjinder
    Singh, Varinder
    CURRENT NEUROPHARMACOLOGY, 2022, 20 (04) : 675 - 692
  • [38] THE ROLE OF β-AMYLOID AND MITOCHONDRIAL DYSFUNCTION IN THE PATHOGENESIS OF ALZHEIMER'S DISEASE
    Szarka Andras
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2015, 68 (7-8): : 222 - 228
  • [39] Mitochondrial Dysfunction-A Pharmacological Target in Alzheimer's Disease
    Eckert, Gunter P.
    Renner, Kathrin
    Eckert, Schamim H.
    Eckmann, Janett
    Hagl, Stephanie
    Abdel-Kader, Reham M.
    Kurz, Christopher
    Leuner, Kristina
    Muller, Walter E.
    MOLECULAR NEUROBIOLOGY, 2012, 46 (01) : 136 - 150
  • [40] Human fibroblasts from sporadic Alzheimer's disease (AD) patients show mitochondrial alterations and lysosome dysfunction
    Li, Yuan
    Li, Zhiquan
    Grillo, Emanuela
    Desler, Claus
    Navarro, Claudia
    Bohr, Vilhelm A.
    Berliocchi, Laura
    Rasmussen, Lene Juel
    FREE RADICAL BIOLOGY AND MEDICINE, 2024, 222 : 569 - 578